Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
|Articles|June 16, 2011

ClinTec International Expands into China, Singapore, and Thailand

UK-based Global Clinical Research Organization , ClinTec International has continued its international expansion by opening fully registered offices in China, Singapore and Thailand—consolidating its presence in the Asia Pacific region. Over the next quarter, strategic moves into South Korea, Taiwan, Malaysia, and Indonesia will also take place. The expansion has also been strengthened by the recent appointment of several regional CRAs plus Mary Pan, Director Asia Pacific who has over 12 years international experience in clinical research.

ClinTec CEO, President and Founder, Dr Buttar commented, “Since ClinTec was established in 1997, entering into the emerging markets has always proved to be a huge success for us and we expect the same from the Asia Pacific market. Several multinational companies in pharmaceutical and clinical nutrition product development are already working in partnership with ClinTec to undertake significant clinical research projects across the region.”

In the current economic climate, pharmaceutical companies are searching for new ways of working and delivering global solutions. As such, they are increasingly looking to enter new markets where revenues have not yet been fully tapped, and for partnerships with global CROs capable of facilitating world-wide multicentre clinical research needs.  In the past two years, ClinTec has entered 25 new countries worldwide.


Related to this article

What Needs to Happen Beyond the Clinical Trial Modernization Act
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.